Translational Research
Volume 155, Issue 4 , Pages 200-208 , April 2010

Type 1 von Willebrand disease due to reduced von Willebrand factor synthesis and/or survival: observations from a case series

  • Alessandra Casonato

      Affiliations

    • Department of Cardiologic, Thoracic, and Vascular Sciences, University of Padua Medical School, Padua, Italy
    • Corresponding Author InformationReprint requests: Alessandra Casonato, MD, Department of Cardiologic, Thoracic, and Vascular Sciences, University of Padua Medical School, Via Ospedale Civile 105, 35128 Padova, Italy
    • ,
  • Lisa Gallinaro

      Affiliations

    • Department of Cardiologic, Thoracic, and Vascular Sciences, University of Padua Medical School, Padua, Italy
    • ,
  • Maria Grazia Cattini

      Affiliations

    • Department of Cardiologic, Thoracic, and Vascular Sciences, University of Padua Medical School, Padua, Italy
    • ,
  • Francesca Sartorello

      Affiliations

    • Department of Cardiologic, Thoracic, and Vascular Sciences, University of Padua Medical School, Padua, Italy
    • ,
  • Elena Pontara

      Affiliations

    • Department of Cardiologic, Thoracic, and Vascular Sciences, University of Padua Medical School, Padua, Italy
    • ,
  • Roberto Padrini

      Affiliations

    • Department of Clinical and Experimental Medicine, University of Padua Medical School, Padua, Italy
    • ,
  • Antonella Bertomoro

      Affiliations

    • Department of Cardiologic, Thoracic, and Vascular Sciences, University of Padua Medical School, Padua, Italy
    • ,
  • Viviana Daidone

      Affiliations

    • Department of Cardiologic, Thoracic, and Vascular Sciences, University of Padua Medical School, Padua, Italy
    • ,
  • Antonio Pagnan

      Affiliations

    • Department of Cardiologic, Thoracic, and Vascular Sciences, University of Padua Medical School, Padua, Italy

Received 16 October 2009 ,Revised 1 December 2009 ,Accepted 2 December 2009.

References 

  1. Sadler JE, Budde U, Eikenboom JC, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand factor. The Working Party on von Willebrand disease classification. J Thromb Haemost. 2006;4:2103–2114
  2. Ruggeri ZM. Von Willebrand factor: looking back and looking forward. Thromb Haemost. 2007;98:55–62
  3. Turitto VT, Weiss HJ, Zimmerman TS, Sussman . Factor VIII/von Willebrand factor in subendothelium mediates platelet adhesion. Blood. 1985;65:823–831
  4. Sadler JE. Biochemistry and genetics of von Willebrand factor. Ann Rev Biochem. 1998;67:395–425
  5. Wagner DD. Cell biology of von Willebrand factor. Ann Rev Cell Biol. 1990;6:217–246
  6. Ruggeri ZM, Pareti FI, Mannucci PM, Ciavarella N, Zimmerman TS. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand disease. N Engl J Med. 1980;302:1047–1051
  7. Mayadas TS, Wagner DD. Vicinal cysteines in the prosequence play a role in von Willebrand factor multimer assembly. Proc Natl Acad Sci U S A. 1992;89:3531–3535
  8. Montgomery RR, Zimmerman TS. Von Willebrand's disease antigen II: a new plasma and platelet antigen deficient in severe von Willebrand's disease. J Clin Invest. 1978;61:1498–1507
  9. Wagner DD, Oemsted JB, Marder VJ. Immunolocalization of von Willebrand factor protein in Weibel-palade bodies of human endothelial cells. J Cell Biol. 1982;95:355–367
  10. van Mourik JA, Boertjes R, Huisveld IA, et al. Von Willebrand factor propeptide in vascular disorders: a tool to distinguish between acute and chronic endothelial cell perturbation. Blood. 1999;94:179–185
  11. Borchiellini A, Fijnvandraat K, ten Cate JW, et al. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-desamino-8-D-arginine vasopressin in humans. Blood. 1996;88:2951–2958
  12. Haberichter SL, Balistreri M, Christopherson P, et al. Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. Blood. 2006;108:3344–3351
  13. Haberichter SL, Castaman G, Budde U, et al. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). Blood. 2008;111:4979–4985
  14. Sztukowska M, Gallinaro L, Cattini MG, et al. Von Willebrand factor propeptide makes it easy to identify the shorter von Willebrand factor survival in patients with type 1 and type Vicenza von Willebrand disease. Brit J Haematol. 2008;143:107–114
  15. Peake I, Goodeve A. Type 1 von Willebrand disease. J Thromb Haemosts. 2007;5:7–11
  16. Sadler JE. Von Willebrand disease type 1: a diagnosis in search of a disease. Blood. 2003;101:2089–2093
  17. Ruggeri ZM, Zimmerman TS. Variant von Willebrand's disease: characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets. J Clin Invest. 1980;65:1318–1325
  18. Casonato A, Pontara E, Sartorello F, et al. Reduced von Willebrand factor survival in type Vicenza von Willebrand disease. Blood. 2002;99:180–184
  19. Brown SA, Eldrige A, Collins PW, Bowen DJ. Increased clearance of von Willebrand factor in type 1 von Willebrand disease: is it a potential pathogenetic process?. J Thromb Haemost. 2003;1:1714–1717
  20. Castaman G, Lethagen S, Federici AB, et al. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood. 2008;111:3531–3539
  21. Sadler JE. A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 1994;71:520–525
  22. Casonato A, Pontara E, Bertomoro A, Sartorello F, Cattini MG, Girolami A. Von Willebrand factor collagen binding activity in the diagnosis of von Willebrand disease: an alternative to ristocetin cofactor activity?. Br J Haematol. 2001;112:578–583
  23. Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker; 1975;
  24. Menache D, Aronson DL, Darr F, et al. Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis. Br J Haematol. 1996;94:740–745
  25. Mancuso DJ, Tuley EA, Westfield LA, et al. Structure of the gene for human von Willebrand factor. J Biol Chem. 1989;264:19514–19527
  26. Goodeve AC, Eikenboom JC, Ginsburg D, et al. A standard nomenclature for von Willebrand factor gene mutations and polymorphisms. On behalf of the ISTH SSC Subcommittee on von Willebrand factor. Thromb Haemost. 2001;85:929–931
  27. Abildgaard CF, Suzuki Z, Harrison J, Jefcoat K, Zimmerman TS. Serial studies in von Willebrand's disease: variability versus variants. Blood. 1980;56:712–716
  28. Casonato A, Daidone V, Sartorello F, et al. Polymorphisms in von Willebrand factor gene promoter influence the glucocorticoid-induced increase in von Willebrand factor: the lesson learned from Cushing's syndrome. Brit J Haematol. 2008;140:230–235
  29. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood. 1987;69:1691–1695
  30. Gallinaro L, Cattini MG, Sztukowska M, et al. A shorter von Willebrand factor survival in O blood group explains how ABO determinants influence plasma von Willebrand factor. Blood. 2008;111:3540–3545
  31. Castaman G, Eikenboom CLJ. ABO blood group influences the von Willebrand factor (VWF) antigen level in heterozygous carriers of VWF null alleles, type 2N Arg854Gln, and the missense mutation Cys2362Phe. Blood. 2002;100:1927–1928
  32. Millar CM, Riddell AF, Brown SA, et al. Survival of von Willebrand factor released following DDAVP in type 1 von Willebrand disease cohort: influence of glycosylation, proteolysis and gene mutations. Thromb Haemost. 2008;99:916–924

 Supported by grants from the Telethon Foundation.

PII: S1931-5244(09)00350-8

doi: 10.1016/j.trsl.2009.12.003

Translational Research
Volume 155, Issue 4 , Pages 200-208 , April 2010

Article Tools

* Image Usage & Resolution